Your browser doesn't support javascript.
loading
Characteristics of Patients with Crohn's Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry.
Fan, Yanni; Delgado-Aros, Sílvia; Valdecantos, Wendell C; Janak, Jud C; Moore, Page C; Crabtree, Margaux M; Stidham, Ryan W.
Afiliación
  • Fan Y; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT, 06877, USA.
  • Delgado-Aros S; Boehringer Ingelheim International GmbH, Binger Str. 173, 55218, Ingelheim, Germany.
  • Valdecantos WC; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT, 06877, USA.
  • Janak JC; CorEvitas, LLC, 1440 Main St, Waltham, MA, 02451, USA.
  • Moore PC; CorEvitas, LLC, 1440 Main St, Waltham, MA, 02451, USA.
  • Crabtree MM; CorEvitas, LLC, 1440 Main St, Waltham, MA, 02451, USA.
  • Stidham RW; Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, 500 S State St, Ann Arbor, MI, 48109, USA. ryanstid@med.umich.edu.
Dig Dis Sci ; 68(1): 214-222, 2023 01.
Article en En | MEDLINE | ID: mdl-35467311
BACKGROUND: There are limited real-world data characterizing perianal fistulae in patients with Crohn's disease (CD). AIM: To describe characteristics of patients with CD with and without perianal fistulae. METHODS: In this cross-sectional study, characteristics, treatment history, and health outcomes of patients with CD enrolled in the CorEvitas IBD Registry were described according to perianal fistula status (current/previous or none). RESULTS: Eight hundred and seventy-eight patients were included. Compared with patients with no perianal fistulae (n = 723), patients with current/previous perianal fistulae (n = 155) had longer disease duration since CD diagnosis (mean 16.5 vs 12.3 years; difference 4.3 years; 95% CI, 2.0, 6.6) and fewer had Harvey-Bradshaw Index scores indicative of remission (0-4, 56.8% vs 69.6%; difference - 12.9%; 95% CI, - 21.6, - 4.2). More patients with current/previous fistulae reported a history of IBD-related emergency room visits (67.7% vs 56.1%; difference 11.6%; 95% CI, 3.4, 19.8), hospitalizations (76.1% vs 58.4%; difference 17.7%; 95% CI, 10.1, 25.4), and surgeries (59.4% vs 27.7%; difference 31.7%; 95% CI, 23.3, 40.1), and a history of treatment with tumor necrosis factor inhibitors (81.3% vs 60.7%; difference 20.6%; 95% CI, 13.5, 27.7), immunosuppressants (51.6% vs 31.2%; difference 20.4%; 95% CI, 11.9, 29.0), and antibiotics (50.3% vs 23.7%; difference 26.6%; 95% CI, 18.2, 35.1) than patients without perianal fistulae. CONCLUSIONS: Patients with CD with current/previous perianal fistulae have more symptomatic experiences of disease, higher medication use, hospitalization rates, and emergency room visits than patients without perianal fistulae. Interventions to prevent/reduce risk of developing fistulae may help improve outcomes in CD.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Crohn / Fístula Rectal Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Dig Dis Sci Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Crohn / Fístula Rectal Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Dig Dis Sci Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos